Share this article on:


JAIDS Journal of Acquired Immune Deficiency Syndromes: April 2012 - Volume 59 - Issue - p 33–36
doi: 10.1097/01.qai.0000413723.17107.77
Abstract Index

101—Understanding How HAART Works

Robert F. Siliciano - Johns Hopkins University School of Medicine

102—A Novel Innate Pathway for Antibody Diversification and Production

Andrea Cerutti - Department of Medicine, Mount Sinai School of Medicine

103—HIV-1 gp120 Interactions With the Gut Homing Receptor Integrin α4β7 on CD4+ T Cells

J. Arthos - NIH/NIAID, Bethesda, MD

104—New Treatment of Hepatitis C Virus Infection

David L. Thomas - Johns Hopkins University School of Medicine

105—New Antivirals and New Antiviral Strategies for HIV

John G. Bartlett - Johns Hopkins University School of Medicine, Baltimore, MD

106—Targeting CCR5 Density for Treatment and Prevention

Robert Redfield - Institute of Human Virology

107—Interleukin-7 As an Immune Reconstitution Agent in HIV-1 Infection: Ex Vivo and in Vivo Protective Effects on CD4+ T Cells

Paolo Lusso - National Institute of Allergy and Infectious Diseases, National Institutes of Health

108—Towards Coitally-Independent Microbicides: Studies with Vaginal Rings and Silicone-Based Gel Delivery Systems

John P. Moore - Cornell University, Weill Medical College

109—HIV-1 Transmission From Semen to the Female Genital Tract and its Prevention, as Seen in an ex vivo Tissue Model

Leonid Margolis- Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health

110—Hard Knocks: Communicating Science to the Public

Paul Offit - The Children's Hospital of Philadelphia

111—Interactions Between HIV Env and Germline Versions of bNAbs

Leonidas Stamatatos - Seattle BioMed, Seattle, WA

112—Diversity of Specificity and Function Among Human Antibodies to Transitional Epitopes Altered by CD4 Binding to the HIV-1 Env Glycoprotein

G. K. Lewis - Institute of Human Virology, University of Maryland School of Medicine

113—Immune Correlates of Infection Risk in the Thai Phase III ALVAC-HIV/AIDSVA-B/E Prime Boost Study

Nelson L. Michael - Walter Reed Army Institute of Research, U.S. Military HIV Research Program

114—Role of Vaccine-Induced V2 Antibodies in Protection from HIV Infection of Recipients in the RV144 Clinical Vaccine Trial

Susan Zolla-Pazner - NYU School of Medicine and New York Veterans Affairs Medical Center

115—DNA and Protein Vaccination via Electroporation Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660

G.N. Pavlakis - Human Retrovirus Section, Vaccine Branch, CCR, NCI, Frederick

116—Autologous and Heterologous Neutralizing Antibody Responses in HIV-1 Infection

David Montefiori - Duke University Medical Center

117—Ending the HIV/AIDS Pandemic: A Realistic Goal

Anthony S. Fauci - National Institute of Allergy and Infectious Diseases, National Institutes of Health

119—Deep Panning - High Resolution Profiling Antibody Specificities

Jonathan M. Gershoni - Department of Cell Research and Immunology, Tel Aviv University

120—Structural Immunology and Vaccine Development

Peter D. Kwong - National Institute of Allergy and Infectious Diseases, National Institutes of Health

121—Effect of Activating KIR Copy Number Variation on NK Cell Containment of SIV Replication in Rhesus Monkeys

Norman L. Letvin - Beth Israel Deaconess Medical Center, Harvard Medical School

122—Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys

Dan H. Barouch - Beth Israel Deaconess Medical Center

123—Vaccine-Elicited Antibodies Contribute to Protective Efficacy, Including Mucosal Antibodies, Correlated with Delayed SIV Acquisition

Marjorie Robert-Guroff - NCI, Bethesda, MD

124—GeoVax HIV/AIDS Vaccine Program, Preclinical and Clinical Studies

Harriet L. Robinson - GeoVax Labs Inc.

125—The Dynamics of Early HIV Infection and a Consequent New Approach to Vaccine Design

James I Mullins - University of Washington

126—Broadly Neutralizing HIV Abs: Gains and Losses in Translation

G. J. Nabel - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health

127—Fighting AIDS Denialism

Nicoli Nattrass - University of Cape Town

128—Toward a Universal Influenza Virus Vaccine

Peter Palese - Department of Microbiology Mount Sinai School of Medicine

129—Live Attenuated Vaccine Induced Mucosal Antibodies and Early Events in the SIV-NHP Model of HIV-1 Transmission to Women

Ashley T. Haase - University of Minnesota

130—Neutralizing and Non-Neutralizing HIV-Specific Antibodies Hinder the Movement of Virus in Fresh Human Cervical Mucus

Thomas J. Hope - Northwestern University Feinberg School of Medicine

131—Characteristics of Transmitted Founder Viruses: Impact of Transmitting Partner Genetics

E. Hunter - University of Alabama at Birmingham

132—Antibodies and Fc Receptors: Their Potential Impact on HIV Infection

Donald Forthal - University of California - Irvine

134—HIV DNA Integration: Mechanism and Consequences

Frederic D. Bushman - University of Pennsylvania School of Medicine

135—Tetherin - Keeping Virions on a Leash

Paul D. Bieniasz - HHMI, ADARC, The Rockefeller University

136—A Roadmap Towards HIV Infection Cure

Alain Lafeuillade - General Hospital

137—Stem Cell Therapy for HIV Disease

Irvin S. Y. Chen - UCLA AIDS Institute

138—Mechanisms of Virus Clearance from the Nervous System

Diane E. Griffin - Johns Hopkins Bloomberg School of Public Health

139—Epitope Masking Mechanism Within the HIV-1 Env Trimer Analyzed by Functional Subunit Complementation

E. A. Berger - Laboratory of Viral Diseases

140—Antiviral Immune Responses, Chronic Immune Activation, and Pattern of Infected Cells in AIDS Pathogenesis: A Lesson from Non-Human Primate Models

Guido Silvestri - Emory University School of Medicine

141—The Role of T Memory Stem Cells: Pathogenesis and Vaccines

Mario Roederer - ImmunoTechnology Section, VRC, NIAID, NIH

142—Cause and Consequence of CD4-Negative T Cell Depletion During HIV Disease

C. David Pauza - Institute of Human Virology, University of Maryland School of Medicine

143—Pediatric HIV Infection: Forging a Path Towards Therapeutic Vaccination

Paolo Rossi - University Department of Paediatrics (DPUO), Children Hospital

144—The Cytosolic Exonuclease TREX1 Digests HIV Reverse Transcripts to Avoid Triggering an Antiviral Interferon Response in T Cells and Macrophages

Judy Lieberman - Immune Disease Institute

145—Pyroptosis and HIV-Induced CD4 T Cell Death

Warner C. Greene - Gladstone Institute of Virology and Immunology, University of California

146—Therapy Against HIV-1/AIDS: Past, Present, Future

Samuel E. Broder - The Children's Hospital of Philadelphia

147—Developing AIDS Associated Cancer Research in Africa

Clement Adebamowo - Institute of Human Virology, Abuja, Nigeria

148—Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Related Multicentric Castleman's Disease (MCD) and Inflammatory Cytokine Syndrome (KICS): Pathogenesis and Treatment

Robert Yarchoan - National Cancer Institute

149—Hepatitis C Virus (HCV)-Related Lymphoproliferative Disorders

Anna Linda Zignego - Center for Systemic Manifestation of Hepatitis Viruses- University of Florence

150—Update on Malignancies Among People with HIV/AIDS

James Goedert - National Cancer Institute, Rockville

151—Virally Associated Malignancies in the HIV Era

Sam M. Mbulaiteye - Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute

152—Can We Cure HTLV-I Associated Adult T Cell Leukemia Lymphoma?

Ali Bazarbachi - American University of Beirut

153—Transformation of Human Cells by HTLV-1 Tax

Kuan-Teh Jeang - National Institute of Allergy and Infectious Diseases

154—Retooling the Macaque Model to Evaluate the Relative Efficacy of HIV Vaccine Candidates

Genoveffa Franchini - National Cancer Institute

155—CD4+CD25+CD127low Regulatory T Cells: MicroRNA Signature and Effect of Valproate on microRNA and FOXP3 Expression Levels

Bassam Badran - Laboratory of Experimental Hematology, Institut Jules Bordet, Universite' Libre de Bruxelles, Bruxelles, Belgium

156—What Happens When Your Viral Flora Gives You Cancer?

Patrick Moore - Cancer Virology Program, University of Pittsburgh Cancer Institute

157—Strategies for Anti-Cancer Immunotherapy Using Vaccines and Blockade of Negative Regulation

Jay A. Berzofsky - Vaccine Branch, CCR, NCI, NIH

© 2012 Lippincott Williams & Wilkins, Inc.